Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.

导出 OA

翻译打印收藏纠错

作者： Benigno,Rodriguez ^[1] ; David M,Asmuth ; Roy M,Matining ; John,Spritzler ; Jeffrey M,Jacobson ; Robbie B,Mailliard ; Xiao-Dong,Li ; Ana I,Martinez ; Allan R,Tenorio ; Franco,Lori ; Julianna,Lisziewicz ; Suria,Yesmin ; Charles R,Rinaldo ; Richard B,Pollard

作者单位： *Division of Infectious Diseases and Center for AIDS Research, Case Western Reserve University/University Hospitals of Cleveland, Cleveland, OH; †Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, CA; ‡Statistical and Data Analysis Center, Harvard School of Public Health, Boston, MA; §Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA; ‖University of Pittsburgh, Pittsburgh, PA; ¶Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD; #Department of Medicine, Rush University Medical Center, Chicago, IL; **ViroStatics srl, Sassari, Italy; ††Genetic Immunity, Budapest, Hungary; ‡‡Genetic Immunity, McLean, VA; and §§Social & Scientific Systems, Inc, Silver Spring, MD. ^[1]